Saleh Ateka, Al-Abcha Abdullah, Pereira Naveen
Department of Molecular Pharmacology and Experimental Therapeutics.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Curr Opin Cardiol. 2023 May 1;38(3):207-214. doi: 10.1097/HCO.0000000000001038. Epub 2023 Mar 28.
Advances in pharmacogenomics have paved the way for personalized medicine. The purpose of this review is to summarize the background, rationale, and evidence for pharmacogenomics in cardiovascular medicine.
Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary interventions. Additionally, there is increasing evidence supporting the association of certain genetic variants and risk of statin associated muscle symptoms. Furthermore, germline genetic variation is being used as a biomarker to target patients with specific therapy.
Pharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of novel drug therapies for cardiovascular disease.
药物基因组学的进展为个性化医疗铺平了道路。本综述的目的是总结心血管医学中药物基因组学的背景、基本原理和证据。
随机临床试验支持了基因型指导方法在接受经皮冠状动脉介入治疗的冠心病患者抗血小板治疗中的作用。此外，越来越多的证据支持某些基因变异与他汀类药物相关肌肉症状风险之间的关联。此外，种系基因变异正被用作一种生物标志物，以确定特定治疗的目标患者。
药物基因组学有潜力通过为合适的患者提供合适的药物来改善患者护理，并可指导心血管疾病新型药物治疗的识别。
